MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

Search

Celldex Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

20.96 -4.64

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

20.71

Max

21.98

Schlüsselkennzahlen

By Trading Economics

Einkommen

-6.7M

-54M

Verkäufe

-480K

695K

Gewinnspanne

-7,740.432

Angestellte

186

EBITDA

-6.7M

-62M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+146.77% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

4.2M

1.4B

Vorheriger Eröffnungskurs

25.6

Vorheriger Schlusskurs

20.96

Nachrichtenstimmung

By Acuity

50%

50%

143 / 375 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Celldex Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Juli 2025, 15:29 UTC

Wichtige Markttreiber

Mustang Bio Shares Jump After Orphan Drug Designation for Cancer Treatment

7. Juli 2025, 23:44 UTC

Market Talk

Nikkei May Fall on U.S. Tariff Concerns -- Market Talk

7. Juli 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Juli 2025, 23:41 UTC

Market Talk

Gold Edges Lower Amid Hopes for Possible Trade Agreements -- Market Talk

7. Juli 2025, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

7. Juli 2025, 23:19 UTC

Market Talk

AML3D Bull Sees Navy Letter Lowering Risks -- Market Talk

7. Juli 2025, 22:20 UTC

Market Talk

Global Equities Roundup: Market Talk

7. Juli 2025, 22:20 UTC

Market Talk

AT&T's Fiber Strategy Positions Stock to Outperform -- Market Talk

7. Juli 2025, 21:34 UTC

Akquisitionen, Fusionen, Übernahmen

BlackRock's Latest Acquisition Is a Commercial Real Estate Bet -- Barrons.com

7. Juli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. Juli 2025, 20:45 UTC

Akquisitionen, Fusionen, Übernahmen

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7. Juli 2025, 20:16 UTC

Market Talk

Canada Bonds Set to Benefit From Rotation Away U.S. Assets -- Market Talk

7. Juli 2025, 19:37 UTC

Market Talk

U.S. Natural Gas Futures Hold Their Ground -- Market Talk

7. Juli 2025, 19:12 UTC

Market Talk

Oil Futures Shrug Off Bigger OPEC+ Output Increase -- Market Talk

7. Juli 2025, 18:33 UTC

Market Talk

Gold Flat as Investors Assess Market Direction -- Market Talk

7. Juli 2025, 18:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Juli 2025, 16:53 UTC

Ergebnisse

Freight Stocks Have a Tariff Overhang. Morgan Stanley Says It Could Be Worse. -- Barrons.com

7. Juli 2025, 16:30 UTC

Market Talk

Higher Prices Limit Power Sector's Natural Gas Use -- Market Talk

7. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. Juli 2025, 16:05 UTC

Akquisitionen, Fusionen, Übernahmen

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7. Juli 2025, 15:41 UTC

Market Talk

Gold Futures Fall as Stronger U.S. Dollar Undermines Safe-Haven Demand -- Market Talk

7. Juli 2025, 15:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7. Juli 2025, 15:40 UTC

Market Talk

Base Metal Prices Tick Lower on U.S. Dollar Strength -- Market Talk

7. Juli 2025, 15:30 UTC

Market Talk

Physical Oil Market Stable But Structural Weakness Looms -- Market Talk

7. Juli 2025, 15:18 UTC

Market Talk

BNP Cuts Brent Forecast on U.S. Shale, Iran Supply Resilience -- Market Talk

7. Juli 2025, 15:14 UTC

Akquisitionen, Fusionen, Übernahmen

MicroStrategy Goes a Week Without Buying Bitcoin. Saylor Has Advice for Crypto Traders. -- Barrons.com

7. Juli 2025, 15:00 UTC

Akquisitionen, Fusionen, Übernahmen

GSK Completes Acquisition of Efimosfermin

7. Juli 2025, 14:52 UTC

Market Talk

Dollar Faces Downward Pressures Stemming from Tariffs -- Market Talk

7. Juli 2025, 14:51 UTC

Market Talk

Bullish Factors Lift Oil Despite Downward Pressure -- Market Talk

7. Juli 2025, 14:45 UTC

Market Talk

Saudi Arabia Not Seeking to Take Oil Market Share -- Market Talk

Peer-Vergleich

Kursveränderung

Celldex Therapeutics Inc Prognose

Kursziel

By TipRanks

146.77% Vorteil

12-Monats-Prognose

Durchschnitt 54.29 USD  146.77%

Hoch 74 USD

Tief 38 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Celldex Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

9

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

18.91 / 20.63Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

143 / 375 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.